Nuclear medicine

BWXT Names Sharon H. Smoot as President of Nuclear Operations Group

Retrieved on: 
Wednesday, July 27, 2022
Defense, Aerospace, Manufacturing, Energy, Other Manufacturing, Nuclear, Other Defense, People, NOG, BWXT, NASA, Twitter, Maintenance, NYSE, Defense News, Old Dominion University, Naval Sea Systems Command, United States Department of Energy, Peter H. Daly (U.S. Navy), Policy, Norfolk Naval Shipyard, Nuclear medicine, BWX Technologies, Command, Department, United States Fleet Forces Command, Fortune 1000, Engineering, Weapon, Management, Renewable energy, Virginia Tech, United States Navy

BWX Technologies, Inc. (NYSE: BWXT) has appointed Sharon H. Smoot as president of BWXTs Nuclear Operations Group, Inc. (NOG).

Key Points: 
  • BWX Technologies, Inc. (NYSE: BWXT) has appointed Sharon H. Smoot as president of BWXTs Nuclear Operations Group, Inc. (NOG).
  • Sharon brings not only proven executive leadership in large, complex industrial and naval operations, but also a reputation for delivering results while inspiring confidence in customers and employees, said Kevin McCoy, president of BWXT Government Operations.
  • She also held positions of increasing responsibility in the Office of the Chief of Naval Operations, U.S. Fleet Forces Command and Norfolk Naval Shipyard.
  • In addition, BWXT joint ventures provide management and operations at more than a dozen U.S. Department of Energy and NASA facilities.

ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board

Retrieved on: 
Friday, July 22, 2022
Radionuclide, Chemistry, CFO, Garching (Munich U-Bahn), III, ITM, Intelligence, Physician, Board of directors, Radiopharmaceutical, Doctor of Philosophy, CEO, Radiation, Research, Neoplasm, Marketing, Technical University of Munich, TUM, Board, Radiochemistry, ITM Group of Institutions, Cancer, Quality of life, Nuclear medicine, Patient, RTÉ Executive Board, Therapy, CBO, Institute of technology, Wilms' tumor, Pharmaceutical industry, Medical imaging

Garching / Munich, July 22, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board as Chief Business Officer (CBO) of the ITM Group.

Key Points: 
  • Garching / Munich, July 22, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board as Chief Business Officer (CBO) of the ITM Group.
  • Dr. Marx joined ITM in 2008 and has since contributed significantly to the companys growth and development across various product management positions, including Head of Sales.
  • We appreciate Sebastians accomplishments over the past 14 years at ITM and warmly welcome him to the Board.
  • The Executive Board of ITM now consists of Steffen Schuster, CEO, Dr. Klaus Maleck, CFO, and Dr. Sebastian Marx, CBO.

DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development

Retrieved on: 
Thursday, July 21, 2022
Rabbit, National, Toxicity, Mortality, Acute radiation syndrome, Deutsch, Red blood cell, Industry, Neutrophil, ISIN, NIAID, Temperature, Radiation, National Institute, MCM, RIM, Infection, Medicine, ARS, Nuclear medicine, Subacute myelo-optic neuropathy, Lymphocyte, Blood, Survival, Mouse, Gesellschaft mit beschränkter Haftung, SDAX, Radiation Sickness, CIM, Pharmaceutical industry, Medical imaging

Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.

Key Points: 
  • Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.
  • Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed Myelo001s excellent safety profile.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Brse.

Curio and Lightbridge Corporation Sign MOU to Explore Collaboration in the Nuclear Fuel Supply Chain

Retrieved on: 
Wednesday, July 20, 2022
GLOBE, U.S. Securities and Exchange Commission, Government, Research, Private Securities Litigation Reform Act, LTBR, Climate change, MOU, Graphite-moderated reactor, Safety, COVID-19, Nuclear energy, NASDAQ, GAIN, Economics, News, The Redstone Acceleration & Innovation Network, Nuclear medicine, Technology, Primary energy, Company, Security (finance), Nasdaq, Department, Annual report, Russell, U.S. Department of Defense Strategy for Operating in Cyberspace, Renewable energy, Uranium, Thanasis Lightbridge, Curio

This collaboration is vital as both Curio and Lightbridge work to develop nuclear technologies that will be key to ushering in the second nuclear era for future generations.

Key Points: 
  • This collaboration is vital as both Curio and Lightbridge work to develop nuclear technologies that will be key to ushering in the second nuclear era for future generations.
  • Our collaboration with Lightbridge is an important step to ensuring there is an adequate fuel supply chain to maintain our current fleet of nuclear reactors and deploy the next generation of reactors, saidEdwardMcGinnis, Chief Executive Officer of Curio.
  • Curios TRUfuel is the fuel of the future, and we stand ready to help the U.S. reclaim global nuclear energy leadership.
  • Lightbridge (NASDAQ: LTBR) is an advanced nuclear fuel technology development company positioned to enable carbon-free energy applications that will be essential in preventing climate change.

DGAP-News: Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply of the Therapeutic Radioisotope Actinium-225 (Ac-225)

Retrieved on: 
Wednesday, July 20, 2022
Radionuclide, Nuclear Physics Institute of the Czech Academy of Sciences, UJF, Deutsch, Board of directors, Camelidae, Radiopharmaceutical, Isotope, Federal Executive Boards, Research, ISIN, CGMP, Leukemia, Cancer, Micrometastasis, Neutralizing antibody, Nuclear medicine, Technology, FDA, Patient, VUB, Actinium-225, Drug Master File, SDAX, Colorectal cancer, Pharmaceutical industry, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) and the Belgian biotech company PRECIRIX NV (PRECIRIX) have signed an agreement for the supply of Actinium-225.
  • This gives PRECIRIX priority access to Eckert & Ziegler's high-purity, non-carrier-added Actinium-225, which is used for the labeling of trial drugs in radionuclide therapy.
  • "Until now, clinical research and commercial use of Actinium-225 has been limited by the shortage of this radioisotope.
  • "We are particularly pleased to have an experienced radioisotope specialist like Eckert & Ziegler at our side to support our ambitious development plans."

Outlook on the Coronary Heart Disease Diagnostic Imaging Devices Global Market to 2030 - Featuring GE Healthcare, Fujifilm, Siemens Healthineer and Toshiba Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022
Health, Medical Devices, Cardiology, Chapter Three, CZT, Acquisition, Patient, CT scan, Hospital, CTCA, National Association Medical Staff Services, CVD, CAGR, Asia-Pacific, Moyamoya disease, Diabetes, Technology, Adoption, Computed tomography angiography, Hypertension, Myocardial perfusion imaging, Death, CHD, Medical imaging, COVID-19, Risk, Growth, Nuclear medicine, Diagnosis, PET, SPECT, Coronary artery disease, Pharmaceutical industry

For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries.

Key Points: 
  • For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries.
  • The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic.
  • Thus, the pandemic significantly impacted the market in 2020, which is likely to stabilize and grow exponentially by 2022.
  • Coronary Heart Disease Diagnostic Imaging Devices Market Variables, Trends & Scope

Kathleen Harper, DO, FACC, FACP is being recognized by Continental Who's Who

Retrieved on: 
Thursday, July 14, 2022
St. Vincent's Hospital, Nuclear medicine, Internal medicine, Internship, St. Vincent's, Society, American College of Cardiology, Sgt. Pepper's Lonely Hearts Club Band (film), Health care, Multimedia, FACP, Continental, University of New England College of Osteopathic Medicine, American Society of Nuclear Cardiology, American College of Physicians, Togus, Maine, Saint Vincent, Patient, Medical degree, American College, American Osteopathic Association, Fellow, Heart failure, DO, American Society of Echocardiography, American Board of Internal Medicine, Medical Center, Woman, Osteopathic medicine in the United States, FACC, Baystate Health, American Board of Commissioners for Foreign Missions, Integrating the Healthcare Enterprise, University, Health, Alternative, Hospital, Medical imaging, Echocardiography, Cardiology

She currently serves a leadership role at Togus VA Medical Center in Maine as the Chief of Cardiology and demonstrates the highest level of medical excellence.

Key Points: 
  • She currently serves a leadership role at Togus VA Medical Center in Maine as the Chief of Cardiology and demonstrates the highest level of medical excellence.
  • She has advocated for women's heart health throughout her career, including preventing cardiac problems and heart failure.
  • She completed her Internship at Humana Hospital, her Residency at St. Vincent's Medical Center, and her Fellowship at University St. Vincent's Medical Center.
  • With a commitment to excellence, Dr. Harper is a distinguished Fellow of the American College of Cardiology (FACC) and the American College of Physicians (FACP).

BWX Technologies to Announce Second Quarter 2022 Results on Monday, August 8

Retrieved on: 
Thursday, July 14, 2022
General Health, Other Energy, Other Manufacturing, Utilities, Oil, Gas, Health, Coal, Health Technology, Alternative Energy, Engineering, Energy, Government Technology, Nuclear, Other Defense, Aerospace, Manufacturing, Defense, People, BWX Technologies, Fortune 1000, United States Department of Energy, Twitter, BWXT, Nuclear medicine, NYSE, NASA, EDT, Internet, International, Defense News, Renewable energy

BWX Technologies, Inc. (BWXT) (NYSE: BWXT) will issue a press release detailing second quarter 2022 results on Monday, August 8, 2022, after market close and will host a conference call at 5:00 p.m. EDT.

Key Points: 
  • BWX Technologies, Inc. (BWXT) (NYSE: BWXT) will issue a press release detailing second quarter 2022 results on Monday, August 8, 2022, after market close and will host a conference call at 5:00 p.m. EDT.
  • Listen-only participants are encouraged to participate and view the supporting presentation via the Internet at www.bwxt.com/investors .
  • The dial-in numbers for participants are (U.S.) 844-200-6205 and (International) 929-526-1599; access code: 875922.
  • At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong, Innovation Driven.

First Patient Enrolled in the Streamlined Localization (STREAMLoc) Registry Study Using SCOUT® at Biopsy in Canada

Retrieved on: 
Wednesday, July 13, 2022
Technology, Radiation therapy, Nuclear medicine, Trauma, Safety, Endoscopy, Breast cancer, Patient, Biopsy, CEO, Radiology, MD, GLOBE, COVID-19, Physician, Observational study, Breast, CHU, Pathology, Cardiology, Health, Radar, MMSI, BI-RADS, Woman, Department, Research, Hospital, University, Efficiency, Critical care, Reading, NASDAQ, Medical imaging

By implanting a tiny reflector, the size of a grain of rice, physicians may be able to precisely target affected tissue.

Key Points: 
  • By implanting a tiny reflector, the size of a grain of rice, physicians may be able to precisely target affected tissue.
  • The STREAMLoc registry study will add to the body of research supporting the use of the SCOUT system to improve efficiency in patient care between biopsy and surgery.
  • This is of high importance, particularly during the ongoing COVID-19 pandemic which has imposed substantial logistical challenges to healthcare delivery in Canada.
  • Study outcomes will be assessed from the initial placement of the SCOUT reflector during biopsy to its removal.

Excel Nuclear Oncology Center in Houston is designated as Radiopharmaceutical Therapy Center of Excellence by SNMMI

Retrieved on: 
Tuesday, July 12, 2022
Knowledge, Compliance, Society of Nuclear Medicine and Molecular Imaging, Google Images, Medical imaging, Patient, SNMMI, IRB, Society, GLOBE, Microsoft Excel, Medical director, CITI, Molecular imaging, Cros, FDA, Research, Nuclear medicine, Certified IRB Professional, Radioligand

HOUSTON, July 12, 2022 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces designation as Radiopharmaceutical Therapy Center of Excellence (RTCOE) by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Key Points: 
  • HOUSTON, July 12, 2022 (GLOBE NEWSWIRE) -- Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces designation as Radiopharmaceutical Therapy Center of Excellence (RTCOE) by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
  • Excel is the first outpatient private facility in the country to receive this honorable designation from SNMMI.
  • Our main mission in the last 15 years has been to address unmet needs in the field of Nuclear Oncology, said Dr. Ebrahim Delpassand, Chairman and Medical Director of EDNOC.
  • EDNOC is fully capable of conducting sponsored clinical research trials in the field of diagnostic and therapeutic nuclear medicine.